E-LIB Suche - Ergebnisse für: Munir, T

1

Richter's transformation: Transforming the clinical landsca..:

Barrett, A. ; Appleby, N. ; Dreau, H....
Blood Reviews. 64 (2024) - p. 101163 , 2024

Link: https://doi.org/10.1016/..

2

STUDY OF GENETIC VARIABILITY IN CHICKPEA GERMPLASM AND ITS ..:

CHEEMA, KL ; SARDAR, S ; AMIN, MA...
Biological and Clinical Sciences Research Journal. 2024 (2024) 1 - p. 798 , 2024

Link: https://doi.org/10.54112..

3

Low dielectric loss, and enhanced magneto-dielectric proper..:

Rehman, Atta Ur ; Sharif, Sehrish ; Hegazy, H.H....
Materials Today Communications. 34 (2023) - p. 105371 , 2023

Link: https://doi.org/10.1016/..

4

DECIPHERING THE GENETIC CODES: GENE ACTION AND COMBINING AB..:

KHAN, Z ; GUL, N ; MEHBOOB, A...
Biological and Clinical Sciences Research Journal. 2023 (2023) 1 - p. 569 , 2023

Link: https://doi.org/10.54112..

5

Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) ..:

Ghia, P. ; Munir, T. ; Burger, J....
Hematological Oncology. 41 (2023) S2 - p. 464-466 , 2023

Link: https://doi.org/10.1002/..

6

Ibrutinib (Ibr) dose modification for management of early c..:

Tedeschi, A. ; Ahn, I. E. ; Fraser, G. A. M....
Hematological Oncology. 41 (2023) S2 - p. 461-463 , 2023

Link: https://doi.org/10.1002/..

7

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE ..:

Shah, NN ; Zinzani, PL ; Eyre, TA...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S359-S360 , 2023

Link: https://doi.org/10.1016/..

8

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FO..:

Fonseca, AR ; Justino, CC ; Molla, VC...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S17 , 2023

Link: https://doi.org/10.1016/..

9

The evolving use of measurable residual disease in chronic ..:

Fisher, A. ; Goradia, H. ; Martinez-Calle, N...
Frontiers in Oncology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

10

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN..:

Shadman, M. ; Munir, T. ; Roback, T....
Hematological Oncology. 41 (2023) S2 - p. 235-238 , 2023

Link: https://doi.org/10.1002/..

11

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023

Link: https://doi.org/10.1002/..

12

P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND A..:

Rawstron, A. ; Webster, N. ; Pitchford, A....
HemaSphere. 6 (2022) - p. 571-572 , 2022

Link: https://doi.org/10.1097/..

13

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere. 6 (2022) - p. 48-49 , 2022

Link: https://doi.org/10.1097/..

14

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS ..:

Hillmen, P. ; Pitchford, A. ; Bloor, A....
HemaSphere. 6 (2022) - p. 46-47 , 2022

Link: https://doi.org/10.1097/..

15

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORA..:

Sharman, J. P. ; Egyed, M. ; Jurczak, W....
HemaSphere. 6 (2022) - p. 564-565 , 2022

Link: https://doi.org/10.1097/..